Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 5/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28644186 | 0.91 | AGTR2 (0.54) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6880139 | 0.88 | HTR2C (0.46) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9175852 | 0.86 | AGTR2 (0.53) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9175859 | 0.86 | AGTR2 (0.53) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6343357 | 0.85 | AGTR2 (0.52) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6285084 | 0.85 | AGTR2 (0.52) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12480716 | 0.85 | AGTR2 (0.49) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14763305 | 0.85 | AGTR2 (0.49) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16256994 | 0.84 | AGTR2 (0.51) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12480005 | 0.84 | AGTR2 (0.51) | AGTR2HTR2CNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512074-B2 | Radiolabeled inhibitors of the amino acid transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150056138-A1 | Radiolabeled Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA | 2015-02-26 | — | — | US | disclosed |
| US-8895607-B2 | Inhibitors of the amino acid transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA (US) | 2014-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056138-A1 | Radiolabeled Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | SLC1A2, SLC1A1, SLC1A3 | AGTR2 1021/4885HTR2C 2239/4885NPC1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.